International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients

Akihiko Nishimura, Junqing Xie, Kristin Kostka, Talita Duarte‐Salles, Sergio Fernández‐Bertolín, María Aragón, Clair Blacketer, Azza Shoaibi, Scott L. DuVall, Kristine E. Lynch, Michael E. Matheny, Thomas Falconer, Daniel R. Morales, Mitchell M. Conover, Seng Chan You, Nicole Pratt, James Weaver, Anthony G. Sena, Martijn J. Schuemie, Jenna Reps, Christian Reich, Peter R. Rijnbeek, Patrick Ryan, George Hripcsak, Daniel Prieto‐Alhambra, Marc A. SuchardFrontiers in Pharmacology 2022 · DOI

TL;DR

This international study investigated whether alpha-1 blockers, commonly used for benign prostatic hyperplasia (BPH), could reduce the risk of COVID-19 infection and its severe complications. Analyzing data from millions of patients across multiple large healthcare databases, the researchers found no significant association between alpha-1 blocker use and a lower risk of COVID-19 diagnosis, hospitalization, or intensive care unit admission.

What Problem Does This Paper Address?

The COVID-19 pandemic spurred a rapid search for effective treatments. One hypothesis suggested that alpha-1 blockers might mitigate the severe inflammatory response (cytokine storm) seen in some COVID-19 patients, potentially by targeting the catecholamine-cytokine axis. This hypothesis was partly inspired by animal studies showing that blocking catecholamines could reduce cytokine release and protect against lethal complications. However, this proposed therapeutic benefit lacked robust real-world evidence, with existing studies having limitations such as small sample sizes and potential for confounding. This paper aimed to address this evidence gap by conducting a large-scale, international observational study to rigorously assess the association between alpha-1 blocker use and COVID-19 outcomes.

Methods

The study employed a prevalent-user active-comparator cohort design, a standard approach in pharmacoepidemiology for evaluating drug effectiveness in real-world settings. They utilized electronic health records and claims data from six large healthcare databases across Spain and the United States. To minimize confounding by indication (where the reason for prescribing a drug might also influence the outcome), they used alpha-1 blockers (alfuzosin, doxazosin, prazosin, silodosin, tamsulosin, terazosin) as the target exposure and other common BPH medications (5-alpha reductase inhibitors and phosphodiesterase type 5 inhibitors) as active comparators.

Key methodological features included:

  • Large-scale Propensity Score (PS) Modeling: To balance baseline characteristics between the exposed (alpha-1 blocker users) and comparator groups, they built extensive PS models incorporating tens of thousands of clinical covariates. This was followed by either PS stratification or matching.
  • Negative Control Outcome Experiments: To assess and correct for residual confounding, they used a set of negative control outcomes for which no association with the exposure was expected. This process helped calibrate the hazard ratios and confidence intervals.
  • Random-Effects Meta-Analysis: To synthesize findings across the different data sources, they performed a meta-analysis, accounting for potential heterogeneity between studies.
  • Open Science Principles: The study protocol, code, and results were made publicly available to ensure transparency and reproducibility.

Datasets

The study leveraged routinely collected electronic health records (EHRs) and claims data from the following sources:

  • SIDIAP (Spain): Covering approximately 80% of the population of Catalonia.
  • US Department of Veterans Affairs (VA) database: Approximately 12 million patients.
  • Columbia University Irving Medical Center (CUIMC) data warehouse: Approximately six million patients.
  • IQVIA OpenClaims: Approximately 160 million patients in the US.
  • Optum De-Identified Clinformatics Data Mart Database (Optum DOD): Approximately 86.8 million patients.
  • Optum De-Identified COVID-19 Electronic Health Record (Optum EHR): Approximately 1.73 million patients.

All data sources were mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDMv5), enabling distributed network analyses without sharing patient-level data.

Key Insights and Ideas

  • Hypothesis Challenged: The study directly tested the hypothesis that alpha-1 blockers could prevent severe COVID-19 outcomes by mitigating cytokine storms. The findings suggest this hypothesis, at least for prevalent users, is not supported by real-world data.
  • The Power of Large-Scale Data and Advanced Methods: The use of multiple, large, real-world databases combined with sophisticated statistical techniques like propensity score matching and negative control calibration was crucial for generating reliable evidence and minimizing biases inherent in observational studies.
  • Importance of Active Comparators: Selecting 5ARI/PDE5 inhibitors as active comparators, rather than simply comparing to unexposed individuals, was key to addressing confounding by indication, a significant challenge when studying BPH medications.
  • Reproducibility and Transparency: The commitment to open science principles (sharing code and data) is a significant contribution, allowing other researchers to verify findings and build upon the work.

Key Results

The study included a total of 2,628,170 users of alpha-1 blockers and 464,525 users of alternative BPH medications (5ARI/PDE5 inhibitors).

  • COVID-19 Diagnosis: The meta-analytic hazard ratio (HR) for COVID-19 diagnosis was 1.02 (95% CI: 0.92-1.13), indicating no significant difference in risk between the groups.
  • COVID-19 Hospitalization: The meta-analytic HR for COVID-19 hospitalization was 1.00 (95% CI: 0.89-1.13), also showing no significant association.
  • Hospitalization Requiring Intensive Services: The meta-analytic HR for hospitalization requiring intensive services was 1.15 (95% CI: 0.71-1.88), which did not reach statistical significance.

Database-specific results were largely consistent, with most showing no statistically significant difference in outcomes.

Limitations and Future Work

The authors acknowledge several limitations:

  • Limited Sample Size for Severe Outcomes: While the study was large, the number of patients experiencing severe COVID-19 outcomes (like intensive services) was still limited, potentially affecting the power to detect smaller effects.
  • Prevalent-User Design: The study used a prevalent-user design due to the low number of new BPH therapy initiations during the pandemic. This design might miss potential benefits of incident (new) use of alpha-1 blockers.
  • Adherence Uncertainty: Patient adherence to prescribed medications cannot be definitively determined from EHR or claims data, although the use of active comparators helps mitigate this.
  • Under-diagnosis/Reporting: The early stages of the pandemic and limited testing availability could lead to under-diagnosis or under-reporting of COVID-19, which might affect the magnitude but not necessarily the direction of the hazard ratios.
  • Generalizability: The study focused on adult men with BPH, so findings may not generalize to other populations.

Future work could focus on determining the potential therapeutic effect of initiating alpha-1 blockers in patients recently infected with SARS-CoV-2, rather than just prevalent users. Further research is also needed to identify effective therapies for COVID-19.

Summary updated

Abstract

<b>Purpose:</b> Alpha-1 blockers, often used to treat benign prostatic hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storm release. The proposed treatment based on this hypothesis currently lacks support from reliable real-world evidence, however. We leverage an international network of large-scale healthcare databases to generate comprehensive evidence in a transparent and reproducible manner. <b>Methods:</b> In this international cohort study, we deployed electronic health records from Spain (SIDIAP) and the United States (Department of Veterans Affairs, Columbia University Irving Medical Center, IQVIA OpenClaims, Optum DOD, Optum EHR). We assessed association between alpha-1 blocker use and risks of three COVID-19 outcomes-diagnosis, hospitalization, and hospitalization requiring intensive services-using a prevalent-user active-comparator design. We estimated hazard ratios using state-of-the-art techniques to minimize potential confounding, including large-scale propensity score matching/stratification and negative control calibration. We pooled database-specific estimates through random effects meta-analysis. <b>Results:</b> Our study overall included 2.6 and 0.46 million users of alpha-1 blockers and of alternative BPH medications. We observed no significant difference in their risks for any of the COVID-19 outcomes, with our meta-analytic HR estimates being 1.02 (95% CI: 0.92-1.13) for diagnosis, 1.00 (95% CI: 0.89-1.13) for hospitalization, and 1.15 (95% CI: 0.71-1.88) for hospitalization requiring intensive services. <b>Conclusion:</b> We found no evidence of the hypothesized reduction in risks of the COVID-19 outcomes from the prevalent-use of alpha-1 blockers-further research is needed to identify effective therapies for this novel disease.
BibTeX
@inproceedings{nishimura2022international,
  author = {Akihiko Nishimura and Junqing Xie and Kristin Kostka and Talita Duarte‐Salles and Sergio Fernández‐Bertolín and María Aragón and Clair Blacketer and Azza Shoaibi and Scott L. DuVall and Kristine E. Lynch and Michael E. Matheny and Thomas Falconer and Daniel R. Morales and Mitchell M. Conover and Seng Chan You and Nicole Pratt and James Weaver and Anthony G. Sena and Martijn J. Schuemie and Jenna Reps and Christian Reich and Peter R. Rijnbeek and Patrick Ryan and George Hripcsak and Daniel Prieto‐Alhambra and Marc A. Suchard},
  title = {{International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.945592},
}
Figure